147 related articles for article (PubMed ID: 32733606)
1. Intrathecal pemetrexed combined with involved-field radiotherapy as a first-line intra-CSF therapy for leptomeningeal metastases from solid tumors: a phase I/II study.
Pan Z; Yang G; He H; Cui J; Li W; Yuan T; Chen K; Jiang T; Gao P; Sun Y; Cong X; Li Z; Wang Y; Pang X; Song Y; Zhao G
Ther Adv Med Oncol; 2020; 12():1758835920937953. PubMed ID: 32733606
[TBL] [Abstract][Full Text] [Related]
2. A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer.
Pan Z; Yang G; Cui J; Li W; Li Y; Gao P; Jiang T; Sun Y; Dong L; Song Y; Zhao G
Front Oncol; 2019; 9():838. PubMed ID: 31544065
[No Abstract] [Full Text] [Related]
3. [Clinical trials on intrathecal pemetrexed treated leptomeningeal metastases from solid tumors].
Pan ZY; Song YY; Jiang TC; Yang X; Yang GZ
Zhonghua Zhong Liu Za Zhi; 2022 Jan; 44(1):112-119. PubMed ID: 35073657
[No Abstract] [Full Text] [Related]
4. Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single-arm study.
Pan Z; Yang G; He H; Zhao G; Yuan T; Li Y; Shi W; Gao P; Dong L; Li Y
Int J Cancer; 2016 Oct; 139(8):1864-72. PubMed ID: 27243238
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of concurrent involved-field radiotherapy and intrathecal chemotherapy for leptomeningeal metastasis from solid tumors.
Pan Z; Chen K; He H; Jiang T; Song Y; Pang X; Ye X; Wang M; Zhou T; Dong L; Yang G
Radiother Oncol; 2023 Sep; 186():109740. PubMed ID: 37315582
[TBL] [Abstract][Full Text] [Related]
6. A Retrospective Study of Intrathecal Pemetrexed Combined With Systemic Therapy for Leptomeningeal Metastasis of Lung Cancer.
Geng D; Guo Q; Huang S; Zhang H; Guo S; Li X
Technol Cancer Res Treat; 2022; 21():15330338221078429. PubMed ID: 35289201
[No Abstract] [Full Text] [Related]
7. Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier: ChiCTR1800016615).
Fan C; Zhao Q; Li L; Shen W; Du Y; Teng C; Gao F; Song X; Jiang Q; Huang D; Jin Y; Lv Y; Wei L; Shi T; Zhao X; Gao N; Jiang Z; Xin T
J Thorac Oncol; 2021 Aug; 16(8):1359-1368. PubMed ID: 33989780
[TBL] [Abstract][Full Text] [Related]
8. Multiple combination therapy based on intrathecal pemetrexed in non-small cell lung cancer patients with refractory leptomeningeal metastasis.
Miao Q; Zheng X; Zhang L; Jiang K; Wu B; Lin G
Ann Palliat Med; 2020 Nov; 9(6):4233-4245. PubMed ID: 33302683
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded, single-arm, phase II clinical trial.
Fan C; Jiang Z; Teng C; Song X; Li L; Shen W; Jiang Q; Huang D; Lv Y; Du L; Wang G; Hu Y; Man S; Zhang Z; Gao N; Wang F; Shi T; Xin T
ESMO Open; 2024 Apr; 9(4):102384. PubMed ID: 38377785
[TBL] [Abstract][Full Text] [Related]
10. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer.
Koba T; Minami S; Nishijima-Futami Y; Masuhiro K; Kimura H; Futami S; Yaga M; Mori M; Kagawa H; Uenami T; Kohmo S; Otsuka T; Yamamoto S; Komuta K; Kijima T
Cancer Chemother Pharmacol; 2018 Jul; 82(1):111-117. PubMed ID: 29728800
[TBL] [Abstract][Full Text] [Related]
12. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.
Zhou C; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Wu F; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J;
Lancet Respir Med; 2021 Mar; 9(3):305-314. PubMed ID: 33347829
[TBL] [Abstract][Full Text] [Related]
13. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC).
Garrido P; Engel-Riedel W; Serke M; Giraud P; Ricardi U; Vallejo C; Visseren-Grul C; Ameryckx S; Soldatenkova V; Chouaki N; Novello S
Lung Cancer; 2015 May; 88(2):160-6. PubMed ID: 25758556
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; RodrÃguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
15. Phase II Study of the Efficacy and Safety of High-dose Pemetrexed in Combination with Cisplatin
He Q; Bi X; Ren C; Wang Y; Zou P; Zhang H; Chi N; Xiu C; Wang Y; Tao R
Anticancer Res; 2017 Aug; 37(8):4711-4716. PubMed ID: 28739776
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma.
Lu Y; Gu W; Deng J; Yang H; Yang W
BMC Cancer; 2016 Oct; 16(1):775. PubMed ID: 27717315
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer.
Zhao X; Yu H; Zhao J; Wu X; Sun S; Luo Z; Wang H; Qiao J; Chang J; Wang J
Oncotarget; 2017 Oct; 8(49):86384-86394. PubMed ID: 29156802
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases.
Kumthekar P; Grimm SA; Avram MJ; Kaklamani V; Helenowski I; Rademaker A; Cianfrocca M; Gradishar W; Patel J; Mulcahy M; McCarthy K; Raizer JJ
J Neurooncol; 2013 Apr; 112(2):247-55. PubMed ID: 23354655
[TBL] [Abstract][Full Text] [Related]
19. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
20. Treatment response to intrathecal chemotherapy with pemetrexed via an Ommaya reservoir in EGFR-mutated leptomeningeal metastases from non-small cell lung cancer: a case report.
Li H; Lin Y; Yu T; Xie Y; Feng J; Huang M; Guo A; Liu X; Yin Z
Ann Palliat Med; 2020 Jul; 9(4):2341-2346. PubMed ID: 32648459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
